Loading clinical trials...
Loading clinical trials...
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more
NCT07495072 · Urinary Bladder Neoplasms, BCG-Induced Cystitis
NCT07222488 · Bladder Cancer, Urinary Bladder Neoplasms
NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, and more
NCT06441110 · Urinary Bladder Neoplasms, BCG Vaccine, and more
Local Institution - 0044
Los Angeles, California
Local Institution - 0081
Riverside, California
Local Institution - 0087
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions